How myeloproliferative neoplasms patients’ experience and expectations differ from physicians’: the international MPN Landmark survey
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Recent advances in the understanding of the pathophysiology of myeloproliferative neoplasms (MPN) were not paralleled with advances in treatment options; thus many questions regarding optimal MPN management remain unanswered. Here, we report the results of descriptive survey study of Korean MPN patients and their attending physicians. Methods: A total of 105 Korean patients (myelofibrosis [MF], 39; polycythemia vera [PV], 25; essential thrombocythemia [ET], 41) and 30 physicians completed the Landmark Health Survey, then data from the survey were analyzed. Results: Among the MPN-Symptom Assessment Form symptoms, the most severe symptom reported was ‘fatigue or tiredness’ in MF and ET patients and ‘itching’ in PV patients. The majority of the patients agreed that MPN reduced their quality of life (QoL). Interestingly, physicians gave higher scores regarding the impact of MPN on patient’s daily and social life compared to patients themselves. For patients, the most important treatment goal was symptom improvement regardless of MPN subtype, while for physicians the highest priority for treatment was better QoL regardless of MPN subtype. Generally, both patients and physicians were satisfied with the overall treatment/management of MPN and communications. However, many patients felt there was not enough time during the appointment for discussion, while many physicians felt they lacked effective drugs to offer to their patients. Conclusions: Our study suggests there are room for better-standardized monitoring of symptoms and treatment options and those continuous efforts to bridge the gap between patients and physicians are necessary for better care of MPN patients.
Abstract
Background/Aims: Recent advances in the understanding of the pathophysiology of myeloproliferative neoplasms (MPN) were not paralleled with advances in treatment options; thus many questions regarding optimal MPN management remain unanswered. Here, we report the results of descriptive survey study of Korean MPN patients and their attending physicians. Methods: A total of 105 Korean patients (myelofibrosis [MF], 39; polycythemia vera [PV], 25; essential thrombocythemia [ET], 41) and 30 physicians completed the Landmark Health Survey, then data from the survey were analyzed. Results: Among the MPN-Symptom Assessment Form symptoms, the most severe symptom reported was ‘fatigue or tiredness’ in MF and ET patients and ‘itching’ in PV patients. The majority of the patients agreed that MPN reduced their quality of life (QoL). Interestingly, physicians gave higher scores regarding the impact of MPN on patient’s daily and social life compared to patients themselves. For patients, the most important treatment goal was symptom improvement regardless of MPN subtype, while for physicians the highest priority for treatment was better QoL regardless of MPN subtype. Generally, both patients and physicians were satisfied with the overall treatment/management of MPN and communications. However, many patients felt there was not enough time during the appointment for discussion, while many physicians felt they lacked effective drugs to offer to their patients. Conclusions: Our study suggests there are room for better-standardized monitoring of symptoms and treatment options and those continuous efforts to bridge the gap between patients and physicians are necessary for better care of MPN patients.
참고문헌 (16)
- Emanuel RM, "Myeloproliferative neoplasm(MPN)symptom assessment form total symptom score : prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs", J Clin Oncol, 30, pp.4098~4103 (2012)
- Scherber R, "The Myeloproliferative Neoplasm Symptom Assessment Form(MPN-SAF) : international prospective validation and reliability trial in 402patients", Blood, 118, pp.401~408 (2011)
- Kralovics R, "A gain-of-function mutation of JAK2 in myeloproliferative disorders", N Engl J Med, 352, pp.1779~1790 (2005)
- Mesa R, "Myeloproliferative neoplasms(MPNs)have a significant impact on patients’ overall health and productivity : the MPN Landmark survey", BMC Cancer, 16, pp.167~ (2016)
- Mesa RA, "Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms(MPNs)and hematologists", oncologists in the United States : findings from the MPN Landmark survey, 2017, pp.123, 449~458
- Harrison CN, "The impact of myeloproliferative neoplasms(MPNs)on patient quality of life and productivity : results from the international MPN Landmark survey", Ann Hematol, 96, pp.1653~1665 (2017)
- Cervantes F, "New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment", Blood, 113, pp.2895~2901 (2009)
- Tefferi A, "Survival and prognosis among 1545 patients with contemporary polycythemia vera : an international study", Leukemia, 27, pp.1874~1881 (2013)
- Passamonti F, "A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis : a study by the International Working Group on Myelofibrosis Research and Treatment", Blood, 120, pp.1197~1201 (2012)
- Alexander JA, "Patient-physician role relationships and patient activation among individuals with chronic illness", Health Serv Res, 47(3 Pt 1), pp.1201~1223 (2012)
- Alexander J, "Patient-physician role relationships and patient activation : the moderating effects of race and ethnicity", Med Care Res Rev, 71, pp.472~495 (2014)
- Mesa RA, "The burden of fatigue and quality of life in myeloproliferative disorders(MPDs) : an international Internet-based survey of 1179 MPD patients", Cancer, 109, pp.68~76 (2007)
- Scherber RM, "Comprehensively understanding fatigue in patients with myeloproliferative neoplasms", Cancer, 122, pp.477~485 (2016)
- Siegel FP, "Aquagenic pruritus in polycythemia vera : characteristics and influence on quality of life in 441 patients", Am J Hematol, 88, pp.665~669 (2013)
- Turner DC, "The role of culture in chronic illness", Am Behav Sci, 39, pp.717~728 (1996)
- Harrison C, "UK results from the myeloproliferative neoplasms(MPN)landmark survey on the symptom, emotional and economic burden of MPN", Br J Haematol, 186, pp.e1~e4 (2019)